Hopp til hovedinnhold
Toggle navigation
Live markets
Search
Search
Search
Search
My profile
My Subscriptions
Watchlists
Quote alerts
Create account
Sign in
NB
FR
EN
PT
NL
NB
DE
IT
Hjem
Company Press Releases
Company press releases
Abonner
Filtre
Filtre
Oppdater
Nullstill
Icon After
Dato
Toggle Visibility
Alle
I dag
Denne uken
Denne måneden
Tilpasset datosøk
Fra
Til
Kategori
Toggle Visibility
Alliances and agreements
Annen informasjonspliktig regulatorisk informasjon
Change in Capital
Commercial operations
Commercial results
Corporate life
Dividend
Eks.dato
Endringer i rettighetene til aksjer / verdipapirer
Flagging
General meeting / Board Meeting
Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll
Ikke-informasjonspliktige pressemeldinger
Income
Innsideinformasjon
Joint venture
Journal / appointments
Kapital- og stemmerettsendringer
Legal
Meetings / events
Meldepliktig handel for primærinnsidere
Mergers, Acquiqitions, Transferts
New
New establishment
News contracts
Other financial transaction
Other subject
Polls / Surveys
Products and services
Prospekt / opptaksdokument
Rapportering om betaling til myndigheter (land-for-land rapportering)
Rating
Renteregulering
Sales
Share history
Share introduction and issues
Takeover bids
Trends / Analyses
Utsteders meldeplikt ved handel i egne aksjer
Valg av hjemstat
Årsrapporter og revisjonsberetninger
Leverandør
Toggle Visibility
ActusNewsWire
BusinessWire
EQS Group
Euronext
GlobeNewswire
Les Echos
Marketwire
Modular Finance
Oslo Børs Newspoint
PR Newswire
Viser 201 - 250 av 278 resultater
Tid
Selskap
Tittel
Sektor
Kategori
21 Feb 2022
08:30 CET
NICOX
ERRATUM - Annule et remplace le précédent communiqué - Nicox : La délivrance d’un nouveau brevet couvre le NCX 470 en Chine jusqu’en 2039
20103015 Pharmaceuticals
New
21 Feb 2022
07:30 CET
NICOX
Nicox : La délivrance d’un nouveau brevet couvre le NCX 470 en Chine jusqu’en 2039
20103015 Pharmaceuticals
New
21 Feb 2022
07:30 CET
NICOX
Nicox Granted New Patent for NCX 470 in China, Extending Coverage to 2039
20103015 Pharmaceuticals
New
08 Feb 2022
07:30 CET
NICOX
Nicox’s Positive FDA Meeting Shows Clear Path for NCX 4251 in Dry Eye
20103015 Pharmaceuticals
New
08 Feb 2022
07:30 CET
NICOX
Nicox : Développement du NCX 4251 dans la sécheresse oculaire à la suite d’une réunion positive avec la FDA américaine
20103015 Pharmaceuticals
New
01 Feb 2022
17:45 CET
NICOX
Number of voting rights as of January 31, 20222
20103015 Pharmaceuticals
Corporate life
01 Feb 2022
17:45 CET
NICOX
Nombre de droits de vote au 31 janvier 2022
20103015 Pharmaceuticals
Corporate life
27 Jan 2022
07:30 CET
NICOX
Nicox to Participate in Financial, Pharmaceutical Industry and Scientific Events in H1 2022
20103015 Pharmaceuticals
New
27 Jan 2022
07:30 CET
NICOX
Nicox : Participation à des conférences financières, d’industrie pharmaceutique et scientifiques au premier semestre 2022
20103015 Pharmaceuticals
New
21 Jan 2022
07:30 CET
NICOX
Nicox Provides Fourth Quarter 2021 Business and Financial Highlights
20103015 Pharmaceuticals
New
21 Jan 2022
07:30 CET
NICOX
Nicox : Point d’activité et résumé financier du quatrième trimestre 2021
20103015 Pharmaceuticals
New
06 Jan 2022
07:30 CET
NICOX
Nicox : Bilan semestriel du contrat de liquidité de la société NICOX
20103015 Pharmaceuticals
New
06 Jan 2022
07:30 CET
NICOX
Nicox: Half-year liquidity contract statement for NICOX
20103015 Pharmaceuticals
New
05 Jan 2022
07:30 CET
NICOX
Nicox : Protection du ZERVIATE par un brevet européen assurant une exclusivité sur cet important marché jusqu’en 2030
20103015 Pharmaceuticals
New
05 Jan 2022
07:30 CET
NICOX
Nicox European Patent Seals ZERVIATE Major Market Coverage to 2030
20103015 Pharmaceuticals
New
03 Jan 2022
18:30 CET
NICOX
Nombre de droits de viote au 31 décembre 2021
20103015 Pharmaceuticals
Corporate life
03 Jan 2022
18:30 CET
NICOX
Number of voting rights as of December 31, 2021
20103015 Pharmaceuticals
Corporate life
16 Dec 2021
07:30 CET
NICOX
Nicox : Pré-sélection du premier patient en Chine dans l’étude de phase 3 Denali en cours sur le NCX 470 dans le glaucome
20103015 Pharmaceuticals
New
16 Dec 2021
07:30 CET
NICOX
Nicox Announces First Patient in China screened in the ongoing NCX 470 Denali Phase 3 Trial in Glaucoma
20103015 Pharmaceuticals
New
13 Dec 2021
07:30 CET
NICOX
Nicox Appoints Doug Hubatsch as new Chief Scientific Officer to lead Clinical and Non-clinical Development
20103015 Pharmaceuticals
New
13 Dec 2021
07:30 CET
NICOX
Nicox : Doug Hubatsch, nouveau Chief Scientific Officer, dirigera le développement clinique et non-clinique
20103015 Pharmaceuticals
New
10 Dec 2021
10:20 CET
NICOX
Nicox : Mise à disposition d'un prospectus d’admission d'actions nouvelles
20103015 Pharmaceuticals
New
09 Dec 2021
15:31 CET
NICOX
Nicox : Mise à disposition d'un amendement au Document d’enregistrement universel 2020
20103015 Pharmaceuticals
New
09 Dec 2021
08:45 CET
NICOX
Nicox Restructures Kreos Capital Bond Financing Agreement and Raises €15 Million in Private Placement
20103015 Pharmaceuticals
New
09 Dec 2021
08:45 CET
NICOX
Nicox Restructures Kreos Capital Bond Financing Agreement and Raises €15 Million in Private Placement
20103015 Pharmaceuticals
-
09 Dec 2021
08:45 CET
NICOX
Nicox restructure l’accord de financement obligataire avec Kreos Capital et lève 15 millions d'euros avec un placement privé
20103015 Pharmaceuticals
New
01 Dec 2021
17:45 CET
NICOX
Number of voting rrights as of November 30, 2021
20103015 Pharmaceuticals
Corporate life
01 Dec 2021
17:45 CET
NICOX
Niombre de droits de vote au 30 novembre 2021
20103015 Pharmaceuticals
Corporate life
30 Nov 2021
07:30 CET
NICOX
Nicox’s Positive Post Hoc Results from NCX 4251 Phase 2b Mississippi Trial Suggest Path Forward in Dry Eye Disease
20103015 Pharmaceuticals
New
30 Nov 2021
07:30 CET
NICOX
Nicox : potentiel pour un développement du NCX 4251 dans la sécheresse oculaire suggéré par des résultats post hoc positifs dans l’étude de phase 2b Mississippi
20103015 Pharmaceuticals
New
17 Nov 2021
07:30 CET
NICOX
Nicox is Granted Patent for Blepharitis Product Candidate NCX 4251 in Europe
20103015 Pharmaceuticals
New
17 Nov 2021
07:30 CET
NICOX
Nicox : Délivrance d’un brevet européen pour le NCX 4251, candidat médicament en développement pour la blépharite
20103015 Pharmaceuticals
New
10 Nov 2021
07:30 CET
NICOX
Nicox’s NCX 470 Dolomites Phase 2 Results in Glaucoma Patients to be Presented at the AAO 2021 Annual Meeting
20103015 Pharmaceuticals
New
10 Nov 2021
07:30 CET
NICOX
Nicox : Présentation à l’AAO 2021 de résultats de l’étude de phase 2 Dolomites sur le NCX 470 chez des patients atteints de glaucome
20103015 Pharmaceuticals
New
02 Nov 2021
17:45 CET
NICOX
Number of voting rightts as of October 31
20103015 Pharmaceuticals
Corporate life
02 Nov 2021
17:45 CET
NICOX
Nombre de droits de vote au 31 octobre 2021
20103015 Pharmaceuticals
Corporate life
19 Oct 2021
07:30 CEST
NICOX
Nicox : Point d’activité et résumé financier du troisième trimestre 2021
20103015 Pharmaceuticals
New
19 Oct 2021
07:30 CEST
NICOX
Nicox Provides Third Quarter 2021 Business and Financial Highlights
20103015 Pharmaceuticals
New
13 Oct 2021
07:30 CEST
NICOX
Nicox : Présentation à la conférence OIS Glaucoma Virtual Innovation Showcase
20103015 Pharmaceuticals
-
13 Oct 2021
07:30 CEST
NICOX
Nicox to present at the OIS Glaucoma Virtual Innovation Showcase
20103015 Pharmaceuticals
-
04 Oct 2021
07:30 CEST
NICOX
Nicox : nouveau site internet
20103015 Pharmaceuticals
New
04 Oct 2021
07:30 CEST
NICOX
Nicox Launches New Corporate & Investor Website
20103015 Pharmaceuticals
New
01 Oct 2021
17:45 CEST
NICOX
Number of voting rights as of September 30,2 021
20103015 Pharmaceuticals
Corporate life
01 Oct 2021
17:45 CEST
NICOX
Nombre de droits de vote au 30 septembre 2021
20103015 Pharmaceuticals
Corporate life
29 Sep 2021
17:45 CEST
NICOX
Nicox confirme son éligibilité au PEA-PME
20103015 Pharmaceuticals
New
29 Sep 2021
07:30 CEST
NICOX
Nicox : Protection des cellules rétiniennes par le NCX 470 montrée dans un modèle non clinique
20103015 Pharmaceuticals
New
29 Sep 2021
07:30 CEST
NICOX
Nicox’s NCX 470 Shows Retinal Cell Protection in a Nonclinical Model
20103015 Pharmaceuticals
New
28 Sep 2021
17:45 CEST
NICOX
Nicox : Rapport semestriel 2021
20103015 Pharmaceuticals
New
27 Sep 2021
07:30 CEST
NICOX
Nicox First Half 2021 Financial Results and Business Update
20103015 Pharmaceuticals
New
27 Sep 2021
07:30 CEST
NICOX
Nicox : Résultats financiers du premier semestre 2021 et point des activités
20103015 Pharmaceuticals
New
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Sider
«
« First
‹
‹‹
4
5
6
›
››
»
Last »
Company press releases subscription
×
To subscribe to Press releases from this issuer, visit the Subscription to Company news section in
Hjem
Markeder
Amsterdam
Cash Products
Aksjer
AEX index Stocks
AEX ESG Stocks
Indekser
Fond
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksopsjoner
Indeksfutures
Aksjeopsjoner
Utbyttederivater
Aksjefutures
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Brussel
Cash products
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
Expert Market
BEL 20 Stocks
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksfutures
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Expert Market
Dublin
Stocks
Euronext regulated
Euronext Growth
ISEQ 20 Stocks
Indices
Funds
Bonds
Irish Government Bonds
DOL
Lisboa
Cash Products
Aksjer
Euronext regulated
Euronext Access
PSI Stocks
Indekser
Obligasjoner
Derivater
Indeksfutures
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Milan
Cash Products
Stocks
Euronext Milan
Euronext Growth Milan
Euronext Star Milan
Euronext Global Equity Market
EuroTLX
Trading After Hours
MIB ESG Stocks
Bonds
MOT
Euronext Access Milan
EuroTLX
Structured Products
SeDeX
EuroTLX
ETFs
Funds
Derivative products
All derivatives
Index futures
Index options
Stock options
Stock futures
Dividend derivatives
Quote Vendor Codes
IPOs
Oslo
Aksjer, renter, indekser
Aksjer
Oslo Børs
Euronext Growth
Euronext Expand
Top performers
OBX aksjer
OBX ESG aksjer
OSEBX aksjer
OSEFX Aksjer
Seafood Aksjer
Shipping Aksjer
Aksjeindekser
Obligasjoner
Oslo Børs
Nordic Alternative Bond Market
Obligasjonsindekser
ETFer
Fond
Derivater
Derivative products
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Finanskalender
Primærinnsidere
Paris
Cash Products
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
CAC 40 Stocks
CAC 40 ESG Stocks
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Aksjer
All Markets directories
All Markets
Euronext regulated
Euronext Growth
Euronext Access
Euronext Expand
Euronext Global Equity Market
EuroTLX
Trading After Hours
Selskapsmeldinger
Latest
Archive
Nye aksjenoteringer
Alle aksjenoteringer
Euronext Growth advisors
Euronext Tech Leaders
Family business
Indekser
Directory
Grønne indekser
Indices documents
Indices news
Indekser høringer
Kontakter Euronext-indekser
ETF-er
Directory
Grønne ETF-er
Fond
Directory
ESG Funds
Oslo Mutual Funds
Obligasjoner
Grønne obligasjoner
1.5° Bonds
All Markets directories
All Markets
Amsterdam
Brussels
Dublin
Lisbon
Oslo
Milan
Paris
Strukturerte produkter
Directory / search
Bid-Only trading status
Trading Turbos in the Netherlands
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
ETF opsjoner
Kontraktsspesifikasjoner
Tick sizes
Rapportering av handler
Leverandørkoder markedsdata
Råvarer
Quotes
Quotes snapshot
Milling Wheat futures
Rapeseed futures
Corn futures
European Durum Wheat Futures
Milling Wheat options
Rapeseed options
Corn options
Bortfallskalendre
Bortfall
Wholesale Trading
Commitments of Traders (CoT) report
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
Knowledge Centre
Bid & Ask
Options Investing E-learning
Contract Specifications
Position Management
Intrinsic Value
Premium & Valuation
Moneyness
Positions
Euronext News
Ressurser
Statistikk & rapporter
Quality of execution
Åpningstider
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
Key Information Document
Class level
Product group level
Notices / Corporate actions
Cash Notices / Corporate actions
Derivatives corporate actions
All Corporate Actions
Latest
Unusual Contract Sizes, Dividends
Corporate Action Services
Corporate Action Policies
Derivatives notices
Markedshendelser
Suspenderte instrumenter
Stressed Market Conditions
Brudd på Double Cap limits
Ekstraordinære markedsforhold
Diverse meldinger
Market status
Medlemsliste
Issuers compliance
Hvor du finner hva